ArticleThe Prostate2026
A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeA key clinical challenge in prostate cancer is the identification and validation of biomarkers with high specificity for indolent long-term outcomes. We applied a novel statistical method to identify tumor transcriptomic biomarkers that optimally predicted patients with low metastatic potential.
methodsUsing tumor whole-transcriptome data from the Health Professionals Follow-up Study (HPFS, discovery set) and Physicians' Health Study (PHS, validation set), we compared patients who died of prostate cancer or developed metastases ("lethal," n = 113) and patients with > 8 years of metastasis-free survival ("indolent," n = 291). Whole transcriptome tumor gene expression data were generated using an Affymetrix array. We applied a novel method for optimizing a partial area under the curve (pAUC) that up-weighted indolent cases with a predefined 80%-100% specificity. This method leverages weighted logistic lasso regression, with weights chosen via cross-validation to reduce overfitting.
resultsMedian age at cancer diagnosis was 66 years; median follow-up for outcomes was 14 years. We identified a 40-gene transcriptome signature of indolent prostate cancer, which, compared to Gleason grade groups, improved the pAUC over the predefined 80%-100% specificity range by 1.72-fold (p < 0.001) and improved overall AUC from 0.85 to 0.93 (p < 0.001). The signature improved positive predictive value for indolent tumors > 2-fold with minimal decrease in negative predictive value. Importantly, the 40-gene signature showed high discrimination among intermediate Gleason 7 tumors (Grade groups 2 and 3, AUC 0.88, 95% CI: 0.79-0.95).
conclusionIncorporating pAUC into prognostic signature development improved identification of prostate tumors with low risk of metastatic potential. Its clinical application may help reduce overtreatment and overdiagnosis of indolent prostate cancers, and the pAUC may be relevant beyond prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.